This national clinical trial aims to identify treatments that may be beneficial for people hospitalised with suspected or confirmed COVID-19
A range of potential treatments have been suggested for COVID-19 but nobody knows if any of them will turn out to be more effective in helping people recover than the usual standard of hospital care which all patients will receive. The RECOVERY Trial is currently testing some of these suggested treatments:
- Low-dose Dexamethasone (now only recruiting children)
- Colchicine (commonly used anti-inflammatory)
- Tocilizumab (an anti-inflammatory treatment given by injection)
- Regeneron’s antibody cocktail (a combination of monoclonal antibodies directed against coronavirus)
- Aspirin (commonly used to thin the blood).
Data from the trial are regularly reviewed so that any effective treatment can be identified quickly and made available to all patients. Please see our news page for results that RECOVERY has already found. The RECOVERY Trial team will constantly review information on new drugs and include promising ones in the trial.
Letters from the Chief Medical Officers
The Chief Medical Officers of England, Wales, Scotland and Northern Ireland, and the NHS Medical Director, have written to all doctors strongly encouraging participation in the national randomised trials in COVID-19 of which RECOVERY is one. You can read the letters by following the links below. Please pass them on to your colleagues.
The importance of increasing recruitment
The importance of COVID-19 clinical trials
Recruiting patients for clinical trials for Covid-19 therapeutics
The RECOVERY Trial is registered at ISRCTN50189673
EU Clinical Trials Register: EudraCT 2020-001113-21
Clinical Trials.gov: NCT04381936
Navigating this site
All study documents, including the Participant Information Sheet and Consent form, and those required by R&D departments and pharmacists, can be downloaded from the For Site Staff area of the site.
The Randomisation Program for sites that will take part in the trial post-training, and all relevant documents can be accessed on the Randomisation page.
The study protocol can be freely downloaded here.
FUNDERS
This trial is supported by a grant to the University of Oxford from UK Research and Innovation/National Institute for Health Research (NIHR) and by core funding provided by NIHR Oxford Biomedical Research Centre, Wellcome, the Bill and Melinda Gates Foundation, the Department for International Development, Health Data Research UK, the Medical Research Council Population Health Research Unit, and NIHR Clinical Trials Unit Support Funding.